Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the overall response rate (ORR) of persistent,
recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.
Phase:
Phase 2
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)